MEDIUMRegulatoryTier 1
Ana Salazar Modela Tu Cuerpo Inc. Issues Nationwide Voluntary Recall of Lipofit Extreme Fat Burner 2.0 Due to Presence of Undeclared Fluoxetine and 2,4-Dinitrophenol (DNP)
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Dental practices that sell or recommend weight-loss supplements to patients must verify product contents, because undeclared prescription drugs (fluoxetine) and toxic DNP could trigger liability or state board complaints if a patient is harmed.
Key points
- The recall targets only Lot 25M12F, exp. 09/2027; practices should immediately pull this lot from inventory or patient give-aways.
- Undeclared fluoxetine (an SSRI) plus the banned substance 2,4-dinitrophenol (DNP) pose serious drug-interaction and hyperthermia risks to medically compromised dental patients.
- FDA has instructed consumer-level recall; dental offices are advised to advise affected patients to stop use and consult their physician.
- No dental-specific devices or materials are involved, so clinical operations are unaffected, but product-liability exposure remains for any practice that distributed the supplement.
Who should care
OwnerStaff
Read the original on FDA Recalls
Full reporting and any paywall content live on fda.gov. We summarize and score; we do not republish.